Lupin informs about press release

27 May 2021 Evaluate

Lupin has informed that it has enclosed a press release on 27th May 2021 as regards the achievement of key milestones for the Company’s MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers. Considered this as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2070.50 15.45 (0.75%)
11-Dec-2025 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.00
Dr. Reddys Lab 1262.05
Cipla 1505.15
Zydus Lifesciences 924.30
Lupin 2070.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×